Therefore, our novel discoveries in CD137 expression in atherothrombotic stroke certainly pave the way for identifying potential biomarkers in atherothrombotic stroke and, more importantly, exploration of a new therapeutic strategy against this human disorder via intervention of the CD137/CD137L pathway. This evidence concerns the gene TNFSF9 and stroke disorder.